

# 1 Fasting and re-feeding independently alter mouse gut microbiota during intermittent 2 fasting

3  
4 Laura D. Schell<sup>1\*</sup>, Yi Jia Liow<sup>1,2</sup>, Rachel N. Carmody<sup>1\*</sup>

5  
6 <sup>1</sup> Department of Human Evolutionary Biology, Harvard University, Cambridge, MA, USA

7 <sup>2</sup> Department of Human Ecology, School of International Health, Graduate School of Medicine, The  
8 University of Tokyo, Bunkyo City, Tokyo, Japan

9  
10 \* Correspondence: Laura D. Schell (lauraschell@g.harvard.edu), Rachel N. Carmody  
11 (carmody@fas.harvard.edu)

12  
13 **Key words:** alternate-day fasting; time-restricted eating; diet cycling; dietary volatility; microbiome  
14 plasticity; lactobacilli; precision nutrition

---

## 17 ABSTRACT (150 words)

18  
19 Intermittent fasting (IF) elicits metabolic benefits that are partially driven by the gut microbiome.  
20 Studies have focused on endpoint IF-induced changes in the gut microbiome but have not  
21 explored whether the oscillating nature of IF elicits day-to-day microbiome changes that could  
22 independently affect health. To discriminate the long-term and short-term effects of IF on the gut  
23 microbiota, we fasted mice every other day (IF1:1) or every two days (IF1:2), measuring daily  
24 changes in body mass and composition, food intake, and gut microbiota composition. We show  
25 that short-term effects of fasting and re-feeding on gut microbiota composition outweigh longer-  
26 term effects of IF treatment, with composition responding differently to re-feeding and fasting.  
27 Re-feeding specifically promoted rapid expansion of *Lactobacillus*, a bacterial genus linked  
28 mechanistically to the metabolic benefits of IF. Our results highlight the plasticity of the gut  
29 microbiota, especially re-feeding effects, as a potential contributor to microbiome-mediated  
30 metabolic benefits of IF.

## 33 INTRODUCTION

34  
35 Intermittent fasting (IF) is known for its metabolic benefits in both humans and animal models,  
36 including weight loss, improved glucose homeostasis, and reduced inflammation<sup>1</sup>. The  
37 metabolic effects of IF have been most commonly linked to reductions in calorie intake,  
38 regulation of circadian rhythms, and the physiological impact of extended fasting periods (i.e.,  
39 activation of repair mechanisms and reduced oxidative stress)<sup>2,3</sup>. However, recent studies  
40 suggest that IF-induced changes in the gut microbiome can also contribute causally to the  
41 metabolic benefits<sup>4</sup>. In a mouse model of every-other-day fasting, mice expended more energy  
42 on fed days, experienced beiging of white adipose tissue, higher body temperature, and  
43 ultimately reduced body fat<sup>4</sup>. Importantly, IF altered the gut microbiota, and transplantation of  
44 the IF-exposed microbiota into obese mice was capable of inducing similar metabolic  
45 improvements even without direct IF treatment. Understanding gut microbial responses to IF  
46 may thus enable us to more effectively harness the therapeutic benefits of IF.

47  
48 The gut microbiota responds rapidly to dietary changes<sup>5,6</sup> and has been shown to regulate  
49 diverse aspects of host energy metabolism, including appetite, nutrient absorption, energy  
50 allocation, and inflammation<sup>7,8</sup>. Numerous studies have found that IF alters the gut microbiota in  
51 animals subjected to every-other-day fasting, as well as in humans under popular IF

52 interventions such as time-restricted eating (daily 12-18h fast), religious fasting, and 5:2 fasting  
53 (2 days/week of minimal calorie intake)<sup>9,10</sup>. Outcomes vary across studies and species, but  
54 common changes under IF include increases in microbial community richness and the relative  
55 abundance *Lactobacillus*<sup>11-14</sup>.

56  
57 However, most studies to date have focused on endpoint changes to the gut microbiota after  
58 weeks to months of IF treatment, overlooking the fact that IF is inherently dynamic, involving  
59 frequent oscillation between the fasted and fed states. This volatility distinguishes IF from other  
60 dietary interventions known to alter the gut microbiota through the static addition or subtraction  
61 of nutrients (e.g., high-fat diets<sup>6</sup>, caloric restriction<sup>15</sup>). In the short-term, both stages of an IF  
62 cycle—fasting and subsequent compensatory overeating during refeeding—could be expected  
63 to influence the gut microbiota by affecting nutrient flows within the gut lumen<sup>16</sup>. In the longer-  
64 term, the intrinsic volatility of the gut environment under IF and the direct impacts of IF on host  
65 metabolism would be expected to exert their own selection pressures on the gut microbiota.

66  
67 Here, we sought to distinguish the short- and long-term impacts of IF on the gut microbiota. We  
68 exposed 6-week-old chow-fed male C57BL/6J mice to every-other-day fasting (IF1:1), every-  
69 two-day fasting (IF1:2) or *ad libitum* feeding (AL) for 30 days (**Figure 1A**). Body mass and food  
70 intake were measured daily; body composition was measured at baseline and endpoint; and  
71 fecal samples were collected for gut microbial profiling on 3 baseline days and then the first 10  
72 and last 10 days of treatment. Our data show that fasting and re-feeding exert dynamic effects  
73 on the gut microbiota that differ from each other and from longer-term microbial signatures of IF.  
74 In particular, we found that re-feeding had a greater impact on the gut microbiota than fasting,  
75 with re-feeding promoting rapid expansion of *Lactobacillus*. The varying short- and long-term  
76 effects of IF on the gut microbiota may influence host metabolism in different ways, suggesting  
77 these dynamics could potentially be exploited to optimize the metabolic response to IF.

78  
79

## 80 RESULTS

81

### 82 ***Intermittent fasting reduces weight gain and total food intake despite compensatory*** 83 ***overeating and lower calorie excretion***

84

85 Both groups of IF mice consumed marginally less total food than AL mice over the course of the  
86 experiment (Wilcoxon rank-sum test,  $P=0.052$ ) (**Figure 1B**). The impact of fasting on total food  
87 intake was partially offset by compensatory overeating by IF mice on the first day of re-feeding  
88 after fasting (re-fed1), when IF1:1 and IF1:2 mice ate an average of 68% and 54% more food  
89 than AL mice, respectively, according to linear mixed effects models (LME) using both mouse ID  
90 and experimental day as random effects (**Figure 1C**). On the second day after fasting (re-fed2),  
91 IF1:2 mice still consumed more food than AL controls, but by a more modest 9% on average.  
92 Over the last two weeks of treatment, IF mice also excreted 3.7% (IF1:1) and 3.3% (IF1:2) fewer  
93 calories in feces than AL controls (**Figure 1D**) suggesting greater fractional energy absorption.  
94 Overall, IF mice compensated for the reduced energy intake of fasting days by overeating on re-  
95 feeding days and excreting fewer calories via feces.

96

97 All mice gained weight over the course of treatment, but IF mice exhibited sharp decreases in  
98 weight on fasted days (**Figure 1E**). By day 30, IF1:1, but not IF1:2, were significantly lighter  
99 than AL mice, and these differences in body mass were attributable to reduced accumulation of  
100 lean mass rather than fat mass (**Figure 1F**). The absence of fat loss in IF mice was likely a  
101 result of their low initial fat mass (**Figure S1A-B**), since we conducted these experiments in

102 healthy mice unlike many other studies focused on effects of IF in mice with obesity due to high-  
103 fat diet exposure or genetic predisposition<sup>9</sup>.

104

105 We next evaluated the extent to which changes in body mass could be explained by reduced  
106 food intake among IF mice using LMEs. Whereas IF1:2 and AL mice on fed days gained similar  
107 amounts of body mass for a given food intake, IF1:1 mice gained 56% less body mass than  
108 expected for their food intake (**Figure 1G**). Thus the more intensive IF1:1 treatment had an  
109 exaggerated impact on host energy balance.

110

111

### 112 ***Short-term feeding oscillations are the strongest determinant of changes to gut*** 113 ***microbiota under IF***

114

115 IF-induced alterations to gut microbial composition were detectable as early as the second cycle  
116 of fasting and re-feeding (PERMANOVA,  $P=0.002$ ,  $R^2=0.16$ ) and persisted through the end of  
117 the study (**Figure 2A**, **Table S1**), despite strong baseline patterning of microbiota composition  
118 by original source cage (PERMANOVA,  $P=0.001$ ,  $R^2=0.56$ ) (**Figure S1C**). IF-induced effects on  
119 the gut microbiota were evident during both fasting and re-fed1 days (**Table S1**), and fasted  
120 days were compositionally distinct from re-fed days (PERMANOVA,  $P=0.001$ ,  $R^2=0.25$ ).

121

122 To distinguish between the short-term impact of feeding status and long-term impacts of IF  
123 treatment, we applied PERMANOVA/adonis tests to the fecal microbiota in the last week of  
124 treatments. The order-dependent nature of the PERMANOVA/adonis test partitions variance  
125 based on the order of variable entry, enabling us to examine the incremental effects of short-  
126 term feeding status given long-term treatment, and vice versa. These analyses showed that  
127 27% of overall variation in the gut microbiota was attributable to IF, of which 2% was ascribable  
128 solely to the long-term effects of treatment, 8% solely to the short-term effects of feeding status,  
129 and 17% to shared (undistinguishable) effects (feeding + treatment:  $R^2_{\text{feeding}} = 0.25$ ,  $R^2_{\text{treatment}} =$   
130  $0.02$ ; treatment + feeding:  $R^2_{\text{feeding}} = 0.08$ ,  $R^2_{\text{treatment}} = 0.19$ ) (**Table S1**). Thus feeding status was  
131 a stronger determinant of microbiota composition than IF treatment itself.

132

133 Both IF treatments reduced absolute bacterial abundance in the gut relative to AL feeding,  
134 particularly on fasted days (**Figure 2B**). This reduction in absolute bacterial abundance is  
135 consistent with predictions based on ecological first principles<sup>17</sup> and reports of similar reductions  
136 in humans on very-low-calorie diets<sup>15</sup>. Despite IF-induced reductions in absolute bacterial  
137 abundance, within-sample taxonomic richness (alpha-diversity) increased among IF1:1 and  
138 IF1:2 mice on fasted and re-fed1 days compared to both baseline and AL-fed controls (**Figure**  
139 **2C**). Enhanced competition between microbes due to the volatility of nutrient availability under  
140 IF may promote taxonomic richness, or else reductions in the absolute abundance of most taxa  
141 may allow for less sensitive, low-abundance taxa to reach detectable levels.

142

143 IF treatment therefore altered the composition, abundance, and diversity of the gut microbiota,  
144 although the type and magnitude of these changes differed by feeding status.

145

146

### 147 ***Gut bacteria respond to both short-term cycling and long-term treatment patterns***

148

149 Different bacterial taxa were independently sensitive to the short-term and long-term features of  
150 IF treatment. Analysis of differentially abundant taxa using MaAsLin3<sup>18</sup> identified 55 genera that  
151 were significantly enriched or depleted during fasting and/or re-feeding relative to baseline and  
152 AL mice (**Figure 3**, **Table S2**).

153  
154 Some genera responded primarily to either fasting or re-feeding, without longer-term changes  
155 attributable to IF treatment. Fasting days were characterized by increases in the relative  
156 abundance of many genera, including *Ruminococcus*, *Akkermansia*, *Thomasclavelia* and 12  
157 others that were elevated during fasting but not re-feeding (**Figure 3, 4A-C, S3A**). By contrast,  
158 re-feeding was characterized largely by an expansive bloom in *Lactobacillus*, which reached a  
159 mean relative abundance of >30% in both IF1:1 and IF1:2 mice on some re-fed1 days (**Figure**  
160 **4D**). Six genera that displayed elevated relative abundance during fasting were also significantly  
161 reduced during re-feeding (**Figure 3**).

162  
163 Other genera responded primarily to long-term IF treatment rather than short-term food cycling,  
164 such as *Turicibacter*, JAGBWK01 (a member of Muribacillaceae), and *Parasuterella*, all of which  
165 were depleted by IF treatment on both fasted and re-fed days (**Figure 4E, S3**). Still other genera  
166 showed both consistent long-term treatment effects and responses to daily food cycling. The  
167 genus *Hominisplanchenecus*, for instance, was elevated during all stages of the IF cycle, with a  
168 greater increase during fasting (**Figure 4F**).

169  
170 Given that IF mice exhibited reduced absolute bacterial abundance on fasted days (**Figure 2B**),  
171 we sought to distinguish whether any of the significant increases in genus relative abundance  
172 during fasting represented increases in absolute abundance or were artifacts driven by absolute  
173 depletions in other taxa (**Figure S2A-B**). Bacteria that reside in the mucus lining like  
174 *Akkermansia*, for instance, might be expected to be more resistant to depletion due to absence  
175 of dietary substrates during fasting, thus showing an increase in relative abundance even if  
176 absolute abundance remained unchanged. We therefore ran MaAsLin3 after scaling bacterial  
177 relative abundance values by the absolute bacterial abundance of each sample (**Table S2**).  
178 With absolute abundance scaling, 37 of the 55 previously identified differentially abundant  
179 genera remained differentially abundant ( $\alpha = 0.05$ , FDR-corrected q values) (**Figure S2C**),  
180 indicating that most changes were not artifacts of reduced bacterial density. However,  
181 coefficients in the scaled models were shifted negatively relative to the unscaled coefficients  
182 (**Figure S2D**). Therefore, the scope and magnitude of these IF-associated increases in relative  
183 abundance were somewhat more modest on an absolute scale, but IF-associated reductions in  
184 relative abundance were also slightly greater in magnitude at an absolute scale.

185

186

### 187 ***Attenuated gut microbiome changes during the second day of re-feeding***

188

189 Given the less frequent fasting of IF1:2 mice, their lesser degree of overeating on re-fed1 and  
190 re-fed2 days, and the reduced long-term impact of IF1:2 treatment on body mass and body  
191 composition, we predicted that IF1:2 mice would experience weaker changes in the gut  
192 microbiota compared with IF1:1 mice. Differences in the gut microbiota between the two  
193 treatments were most evident on re-fed2 days, which were compositionally distinct from both re-  
194 fed1 days (PERMANOVA,  $P=0.001$ ,  $R^2=0.06$ ) and fasting days ( $P=0.001$ ,  $R^2=0.08$ ). Re-fed2-  
195 associated changes to the fecal microbiota were attenuated relative to re-fed1 day in terms of  
196 overall compositional distance from baseline and AL controls (**Figure 2E, S1E**) and differentially  
197 abundant microbes (**Figure 3**). Absolute bacterial abundances on re-fed2 days were  
198 indistinguishable from those of AL controls (**Figure 2B**), suggesting rapid recovery of microbial  
199 biomass after a single day of re-feeding.

200

201 Outside of re-fed2 days, gut microbiota differences between IF1:2 and IF1:1 treatment were  
202 detectable but limited in scope. Over the last week of treatment, IF1:2 microbiota differed from  
203 IF1:1 microbiota on matched fasted and re-fed-1 days, but these differences had relatively small

204 effect sizes (PERMANOVA,  $P=0.001$ ,  $R^2=0.03$ ) (**Table S1**). Accounting for differences by  
205 treatment group in MaAsLin3 models, we detected an attenuated increase in the relative  
206 abundance of *Thomasclavelia* among IF1:2 mice during fasting ( $P=0.016$ ), but this difference  
207 did not reach significance when controlling for total bacterial abundance ( $P=0.429$ ) (**Figure 4C**).  
208 Therefore, to the extent that reduced weight loss under IF1:2 versus IF1:1 treatment was linked  
209 to changes in the gut microbiota, this was likely due to reduced frequency of fasting and re-fed1  
210 days rather than any unique impact of IF1:2 treatment on the gut microbiota.

211  
212

### 213 **Re-feeding promotes *Lactobacillus* and drives greater changes in gut microbiota** 214 **composition than fasting**

215

216 Each cycle of fasting and re-feeding drove consistent oscillations in gut microbial composition,  
217 but it was the gut microbiota during re-feeding, rather than fasting, that differed most from the  
218 AL fed state. Principal coordinate analysis of Bray-Curtis distance between samples shows that  
219 gut microbiota signatures on re-fed days shifted away from AL and baseline signatures along  
220 PCo1 and PCo2, whereas fasted days were intermediate between re-fed and AL signatures  
221 (**Figure 2D, S1D**). Additionally, re-fed gut microbiota were more dissimilar than fasted gut  
222 microbiota relative to baseline (**Figure 2E**) and to day-matched AL mice (**Figure S1E**).

223

224 The main compositional shift underlying gut microbiota changes during re-feeding was a bloom  
225 in *Lactobacillus*, which reached >30% relative abundance on many re-fed1 days in both IF1:1  
226 and IF1:2 mice and >50% relative abundance in some IF1:1 mice (**Figure 4D**). Changes in  
227 *Lactobacillus* have been previously observed in mice exposed to IF<sup>11-14</sup>, and the genus is  
228 notable for its rapid growth and ability to ferment carbohydrates to produce acetate and  
229 lactate<sup>19</sup>. During IF, the larger influx of food on re-fed1 days likely caused more nutrients to  
230 escape host digestion, potentially allowing endogenous *Lactobacillus* to expand rapidly and  
231 temporarily outcompete slower-growing taxa. Importantly, previous mouse models of IF1:1  
232 linked metabolic improvements to gut microbial production of acetate and lactate that  
233 subsequently promoted adipocyte beiging and thermogenesis, with higher total energy  
234 expenditure on re-feeding days<sup>4</sup>. Acetate, lactate, *Lactobacillus*, and other commensal lactic  
235 acid bacteria have also been shown to promote brown fat thermogenesis in other contexts<sup>20-22</sup>.  
236 Together, these results suggest that expansion of *Lactobacillus* in response to re-feeding—but  
237 not during fasting—may underpin microbiome-mediated metabolic improvements with IF  
238 treatment. This re-feeding-focused view contrasts with conventional focus among IF  
239 researchers on the physiological impacts of extended fasting, suggesting that both may be  
240 important in eliciting the metabolic benefits of IF.

241

242

## 243 **DISCUSSION**

244

245 Intermittent fasting poses a unique ecological challenge for gut microbes, given its alterations to  
246 the gut environment on both short- and long-term timescales. In our experiments involving  
247 every-other-day (IF1:1) and every-two-day (IF1:2) fasting, mice lost weight and absolute gut  
248 bacterial abundance was roughly halved on average during fasting. That fasting should impact  
249 the microbiome is unsurprising, as very-low-calorie diets and ketogenic diets that induce fasting-  
250 like physiological responses in the host have been shown to affect gut microbiome composition  
251 and function<sup>15,23</sup>. However, our work emphasizes that compensatory overeating during the re-  
252 feeding period may be just as important as fasting in shaping the impact of intermittent fasting  
253 on the gut microbiome.

254

255 Our study underscored that the impacts of fasting and re-feeding on the gut microbiota are  
256 distinct. On the first day of re-feeding, when IF mice consumed >50% more food than expected,  
257 the gut microbiota exhibited the starkest differences from baseline and *ad libitum*-fed controls. In  
258 both IF1:1 and IF1:2 groups, the gut microbiota on the first day of re-feeding showed a  
259 particularly large expansion of *Lactobacillus*, a bacterial genus previously found to be enriched  
260 with IF<sup>11-14</sup> and causally linked to the metabolic benefits of IF via acetate and lactate  
261 production<sup>4</sup>. Crucially, our data suggest that elevated post-fast re-feeding, rather than fasting or  
262 IF treatment *per se*, may account for these microbiota-mediated benefits, although additional  
263 mechanistic testing is required to confirm this hypothesis.

264  
265 While the IF1:1 and IF1:2 fasting models employed here are ideal for understanding the  
266 ecological impact of fasting and re-feeding cycles on the gut microbiota, such day-to-day  
267 variation will be harder to detect in humans given our substantially longer gastrointestinal transit  
268 times (12-72 hr in humans<sup>24,25</sup>, 2-6 hr in mice<sup>26,27</sup>). This would be especially true given the  
269 shorter fasting periods of time-restricted eating regimens, in which food is consumed during a 6-  
270 10-hr window each day. However, lack of sampling resolution does not preclude the possibility  
271 that such short-term changes to the gut microbiome during IF do occur in humans. Previous  
272 studies have consistently reported IF-associated changes in gut microbiota composition<sup>9,10</sup>,  
273 although the inability to reliably link samples to either the fasted or re-fed state likely adds  
274 considerable noise to experimental outcomes. New technologies for *in vivo* sampling in healthy  
275 humans<sup>28</sup> will be an important tool for future translational research in this area.

276  
277 In conclusion, our study showed that, during IF treatment, the gut microbiota responds uniquely  
278 to each stage of the feeding cycle, with additional changes under long-term treatment. Evidence  
279 that microbiota changes previously linked to the metabolic benefits of IF were restricted to the  
280 re-feeding stage complements current research emphasis on fasting and suggests that both  
281 stages may offer important levers for maximizing health benefits. Further research is necessary  
282 to establish this pattern in humans and to determine whether the long-term impacts of IF on the  
283 microbiome result from changes to host physiology or compounding selective pressures on the  
284 gut microbiota with each additional feeding cycle.

285  
286

## 287 **ACKNOWLEDGEMENTS**

288 This work was supported by funding from NIGMS 1R35GM160067 (RNC), NSF BCS-2142073  
289 (LDS and RNC), NSF Graduate Research Fellowship (LDS), JSPS KAKENHI Grants-in-Aid for  
290 Scientific Research 23KJ0457 (YJL), and the William F. Milton Fund (RNC). The authors thank  
291 our colleagues in the Nutritional and Microbial Ecology Lab for feedback on early drafts, and  
292 particularly Michelle Stegawski for her work on fecal bomb calorimetry. We also thank staff  
293 members of Harvard University's Bauer Core Facility, Office of Animal Resources, and  
294 Biological Research Infrastructure for their assistance with sequencing and animal work,  
295 respectively. The content of this article is solely the responsibility of the authors and does not  
296 necessarily represent the official views of the National Institutes of Health.

297

## 298 **COMPETING INTERESTS**

299 The authors declare they have no competing interests.

300

## 301 **AUTHOR CONTRIBUTIONS**

302 This study was conceived and designed by LDS and RNC. All animal work and sample  
303 collection was performed by LDS. Sample processing was performed by LDS and YJL. Data  
304 were analyzed by LDS. Manuscript was written by LDS and RNC with contributions and final  
305 approval of all authors.

306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356

## **DATA AND CODE AVAILABILITY**

The 16S rRNA gene sequencing data described in this study are available in the NCBI Sequence Read Archive under BioProject number PRJNA1428163. All other data and the code used to analyze data and generate figures will be made available upon reasonable request.

## **METHODS**

### **Animal husbandry**

Male C57BL/6J mice were individually housed under specific pathogen-free conditions in Harvard University's Biological Research Infrastructure facility and maintained on a standard chow diet (Prolab IsoPro RMH 3000) and 12h:12h light/dark cycle for the duration of the study. Food was weighed and added or removed at ~8 hours into the light cycle each day, and during these interventions data on body mass and fecal samples were collected. Wellness checks were performed daily to identify any potential adverse responses to treatment, and no mice were excluded from the study. All animal work was reviewed and approved by the Harvard University Institutional Animal Care and Use Committee under protocol #17-06-306.

### **Body composition measurement**

Lean body mass and fat mass of live animals were quantified using an EchoMRI-100H system (EchoMRI, Houston, TX).

### **Quantification of fecal energy density**

Cage bottoms from the last 2 weeks of the study period were collected and sifted to separate fecal material. Between 1.7-2.0 g of fecal material was combusted in a Parr 6050 Bomb Calorimeter (Parr Instrument Company, Moline, IL) to quantify caloric density.

### **Fecal DNA isolation**

Fresh fecal samples were collected directly from mice, immediately flash frozen in liquid nitrogen, and stored at -80°C until processing. DNA was extracted using the E.Z.N.A Soil DNA kit (Omega BioTek, Norcross, GA) according to manufacturer instructions.

### **Quantification of absolute bacterial abundance**

Bacterial abundance was quantified in fecal DNA extracts via qPCR targeting the V4 region of the 16S rRNA gene, with assays performed in triplicate. To set up reactions, 2 µl template DNA was combined with 5 µl PowerUp SYBR Green Mix (2X) (ThermoFisher, Waltham, MA), 2 µl nuclease-free water, and 0.5 µl each of 10 nM unbarcoded primers (515F, 806R). Reactions were run on a BioRad CFX 96-well real-time PCR thermocycler (BioRad Laboratories, Waltham, MA) with the following protocol: enzyme activation for 2 min at 50°C; initial denature for 2 min at 95°C; then 40 cycles of 95°C for 3 sec and 60°C for 30 sec. Any replicates with a quantification threshold (Cq) ≥1 different from the sample mean were excluded, and samples with ≥2 replicates meeting these criteria were re-run. Bacterial 16S rRNA gene concentrations were calculated against a standard curve of genomic DNA isolated from a pure culture of *E. coli* and a conversion factor of  $2.03 \times 10^5$  (based on an estimated mean gut bacterial genome size of 4.50 Mbp)<sup>29</sup> was used to calculate bacterial genome equivalents.

### **16S rRNA gene sequencing**

DNA extracts were prepared for sequencing as described previously<sup>30</sup>. Briefly, the V4 region of the 16S rRNA gene was PCR-amplified with barcoded primers (515F, 806R), run on a gel to confirm amplification and ensure no contamination was present. PCR amplicons were then

357 quantified using the Quant-iT Picogreen dsDNA Assay Kit (Invitrogen, Carlsbad, CA), pooled  
358 evenly according to DNA concentration, cleaned using AmpureXP beads (Agencourt, Brea, CA),  
359 then gel-purified and extracted using the Qiaquick Gel Extraction Kit (Qiagen, Hilden, Germany).

360  
361 Prepared 16S libraries were sequenced 2x150 bp on one lane of an Illumina NovaSeq S1  
362 platform, with a 30% PhiX spike-in to provide sequence diversity. Demultiplexed sequences  
363 were processed using Qiime2<sup>31</sup> and denoised with Dada2<sup>32</sup>, truncating at 149 bp to optimize  
364 read quality. A total of 123,663,276 reads, representing 412 samples (median 291,487  
365 reads/sample) and 1,355 unique amplicon sequence variants (ASVs), were retained after quality  
366 filtering. Sequence taxonomy was assigned using a qiime2 pre-trained classifier for the  
367 515F/806R region based on the Greengenes2 2024.09 database<sup>33</sup>. Further processing was  
368 performed in R (v4.5.1) using qiime2R (v0.99.6) for the initial import and phyloseq (v1.52.0) for  
369 preprocessing and subsequent analysis. Data were pre-processed by pruning low-abundance  
370 ASVs (defined as <3 reads across all samples) and rarefied to 40,000 reads/sample for even  
371 sequencing depth, which resulted in a total of 965 ASVs being represented across our 412  
372 samples.

### 373 374 **Statistical methods**

375 All statistical tests were performed in R (v4.5.1). For cross-sectional comparisons, we applied  
376 either t-tests or Wilcoxon rank-sum tests for normal- and non-normally distributed data,  
377 respectively, as determined by the Shapiro-Wilkes test. Unless otherwise specified, all  
378 comparisons used the AL treatment group or AL-fed state (baseline and AL group) as a  
379 reference, and multiple hypothesis testing was corrected using the Holm-Bonferroni method. For  
380 analyses across the longitudinal dataset, linear mixed effects models were applied with the nlme  
381 package (v3.1-168) and comparisons between the coefficients for different variable levels were  
382 performed using Tukey's Honest Significant Difference test via the lsmeans package (v2.30-2).

383  
384 Overall microbiome composition differences were assessed using PERMANOVA/adonis2 tests  
385 via the vegan package (v2.7-2). Identification of differentially abundant genera was performed  
386 using MaAsLin3<sup>18</sup> (v1.1.2), which applies linear mixed effects models to log-transformed data  
387 and corrects for multiple hypothesis testing with the false discovery rate (FDR) correction.

### 388 389 390 **REFERENCES**


- 391  
392 1. Patterson, R.E., and Sears, D.D. (2017). Metabolic effects of intermittent fasting. *Annu. Rev.*  
393 *Nutr.* 37, 371–393.
- 394 2. Vasim, I., Majeed, C.N., and DeBoer, M.D. (2022). Intermittent fasting and metabolic health.  
395 *Nutrients* 14, 631.
- 396 3. Longo, V.D., Di Tano, M., Mattson, M.P., and Guidi, N. (2021). Intermittent and periodic  
397 fasting, longevity and disease. *Nat. Aging* 1, 47–59.
- 398 4. Li, G., Xie, C., Lu, S., Nichols, R.G., Tian, Y., Li, L., Patel, D., Ma, Y., Brocker, C.N., Yan, T.,  
399 et al. (2017). Intermittent fasting promotes white adipose browning and decreases obesity  
400 by shaping the gut microbiota. *Cell Metab.* 26, 672–685.
- 401 5. David, L.A., Maurice, C.F., Carmody, R.N., Gootenberg, D.B., Button, J.E., Wolfe, B.E.,  
402 Ling, A.V., Devlin, A.S., Varma, Y., Fischbach, M.A., et al. (2014). Diet rapidly and  
403 reproducibly alters the human gut microbiome. *Nature* 505, 559–563.

- 404 6. Carmody, R.N., Gerber, G.K., Luevano, J.M., Jr, Gatti, D.M., Somes, L., Svenson, K.L., and  
405 Turnbaugh, P.J. (2015). Diet dominates host genotype in shaping the murine gut microbiota.  
406 *Cell Host Microbe* 17, 72–84.
- 407 7. Carmody, R.N., and Bisanz, J.E. (2023). Roles of the gut microbiome in weight  
408 management. *Nat. Rev. Microbiol.* 21, 535–550.
- 409 8. Carmody, R.N., Varady, K., and Turnbaugh, P.J. (2024). Digesting the complex metabolic  
410 effects of diet on the host and microbiome. *Cell* 187, 3857–3876.
- 411 9. Mousavi, S.N., Rayyani, E., Heshmati, J., Tavasolian, R., and Rahimlou, M. (2022). Effects  
412 of Ramadan and non-ramadan intermittent fasting on gut microbiome. *Front. Nutr.* 9,  
413 860575.
- 414 10. Paukkonen, I., Törrönen, E.-N., Lok, J., Schwab, U., and El-Nezami, H. (2024). The impact  
415 of intermittent fasting on gut microbiota: a systematic review of human studies. *Front. Nutr.*  
416 11, 1342787.
- 417 11. Shi, H., Zhang, B., Abo-Hamzy, T., Nelson, J.W., Ambati, C.S.R., Petrosino, J.F., Bryan,  
418 R.M., Jr, and Durgan, D.J. (2021). Restructuring the gut microbiota by intermittent fasting  
419 lowers blood pressure. *Circ. Res.* 128, 1240–1254.
- 420 12. Zhang, Z., Chen, X., Loh, Y.J., Yang, X., and Zhang, C. (2021). The effect of calorie intake,  
421 fasting, and dietary composition on metabolic health and gut microbiota in mice. *BMC Biol.*  
422 19, 51.
- 423 13. Liu, J., Zhong, Y., Luo, X.M., Ma, Y., Liu, J., and Wang, H. (2021). Intermittent fasting  
424 reshapes the gut microbiota and metabolome and reduces weight gain more effectively than  
425 melatonin in mice. *Front. Nutr.* 8, 784681.
- 426 14. Cignarella, F., Cantoni, C., Ghezzi, L., Salter, A., Dorsett, Y., Chen, L., Phillips, D.,  
427 Weinstock, G.M., Fontana, L., Cross, A.H., et al. (2018). Intermittent fasting confers  
428 protection in CNS autoimmunity by altering the gut microbiota. *Cell Metab.* 27, 1222–1235.
- 429 15. von Schwartzberg, R.J., Bisanz, J.E., Lyalina, S., Spanogiannopoulos, P., Ang, Q.Y., Cai,  
430 J., Dickmann, S., Friedrich, M., Liu, S.-Y., Collins, S.L., et al. (2021). Caloric restriction  
431 disrupts the microbiota and colonization resistance. *Nature* 595, 272–277.
- 432 16. Venable, E.M., and Carmody, R.N. (2024). Decoupled Nutrient Status: a framework to  
433 disentangle host from microbial responses to diets that vary in digestibility. *Front. Food Sci.*  
434 *Technol.* 4, 1469470.
- 435 17. Reese, A.T., Pereira, F.C., Schintlmeister, A., Berry, D., Wagner, M., Hale, L.P., Wu, A.,  
436 Jiang, S., Durand, H.K., Zhou, X., et al. (2018). Microbial nitrogen limitation in the  
437 mammalian large intestine. *Nat. Microbiol.* 3, 1441–1450.
- 438 18. Nickols, W.A., Kuntz, T., Shen, J., Maharjan, S., Mallick, H., Franzosa, E.A., Thompson,  
439 K.N., Nearing, J.T., and Huttenhower, C. (2026). MaAsLin 3: refining and extending  
440 generalized multivariable linear models for meta-omic association discovery. *Nat. Methods*,  
441 1–11.

- 442 19. Walter, J. (2008). Ecological role of lactobacilli in the gastrointestinal tract: implications for  
443 fundamental and biomedical research. *Appl. Environ. Microbiol.* *74*, 4985–4996.
- 444 20. Cani, P.D., Van Hul, M., Lefort, C., Depommier, C., Rastelli, M., and Everard, A. (2019).  
445 Microbial regulation of organismal energy homeostasis. *Nat. Metab.* *1*, 34–46.
- 446 21. Hossain, M., Park, D.-S., Rahman, M.S., Ki, S.-J., Lee, Y.R., Imran, K.M., Yoon, D., Heo, J.,  
447 Lee, T.-J., and Kim, Y.-S. (2020). *Bifidobacterium longum* DS0956 and *Lactobacillus*  
448 *rhamnosus* DS0508 culture-supernatant ameliorate obesity by inducing thermogenesis in  
449 obese-mice. *Benef. Microbes* *11*, 361–373.
- 450 22. Chen, L.-H., Chen, Y.-H., Cheng, K.-C., Chien, T.-Y., Chan, C.-H., Tsao, S.-P., and Huang,  
451 H.-Y. (2018). Antiobesity effect of *Lactobacillus reuteri* 263 associated with energy  
452 metabolism remodeling of white adipose tissue in high-energy-diet-fed rats. *J. Nutr.*  
453 *Biochem.* *54*, 87–94.
- 454 23. Ang, Q.Y., Alexander, M., Newman, J.C., Tian, Y., Cai, J., Upadhyay, V., Turnbaugh, J.A.,  
455 Verdin, E., Hall, K.D., Leibel, R.L., et al. (2020). Ketogenic diets alter the gut microbiome  
456 resulting in decreased intestinal Th17 cells. *Cell* *181*, 1263–1275.
- 457 24. Asnicar, F., Leeming, E.R., Dimidi, E., Mazidi, M., Franks, P.W., Al Khatib, H., Valdes, A.M.,  
458 Davies, R., Bakker, E., Francis, L., et al. (2021). Blue poo: impact of gut transit time on the  
459 gut microbiome using a novel marker. *Gut* *70*, 1665–1674.
- 460 25. Nandhra, G.K., Mark, E.B., Di Tanna, G.L., Haase, A.-M., Poulsen, J., Christodoulides, S.,  
461 Kung, V., Klinge, M.W., Knudsen, K., Borghammer, P., et al. (2020). Normative values for  
462 region-specific colonic and gastrointestinal transit times in 111 healthy volunteers using the  
463 3D-Transit electromagnet tracking system: Influence of age, gender, and body mass index.  
464 *Neurogastroenterol. Motil.* *32*, e13734.
- 465 26. Gama, L.A., Rocha Machado, M.P., Beckmann, A.P.S., Miranda, J.R. de A., Corá, L.A., and  
466 Américo, M.F. (2020). Gastrointestinal motility and morphology in mice: Strain-dependent  
467 differences. *Neurogastroenterol. Motil.* *32*, e13824.
- 468 27. Kashyap, P.C., Marcobal, A., Ursell, L.K., Larauche, M., Duboc, H., Earle, K.A.,  
469 Sonnenburg, E.D., Ferreyra, J.A., Higginbottom, S.K., Million, M., et al. (2013). Complex  
470 interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice.  
471 *Gastroenterology* *144*, 967–977.
- 472 28. Shalon, D., Culver, R.N., Grembi, J.A., Folz, J., Treit, P.V., Shi, H., Rosenberger, F.A.,  
473 Dethlefsen, L., Meng, X., Yaffe, E., et al. (2023). Profiling the human intestinal environment  
474 under physiological conditions. *Nature* *617*, 581–591.
- 475 29. Roopchand, D.E., Carmody, R.N., Kuhn, P., Moskal, K., Rojas-Silva, P., Turnbaugh, P.J.,  
476 and Raskin, I. (2015). Dietary polyphenols promote growth of the gut bacterium  
477 *Akkermansia muciniphila* and attenuate high-fat diet-induced metabolic syndrome. *Diabetes*  
478 *64*, 2847–2858.
- 479 30. Schell, L.D., Rubin, G., Chan, E., and Carmody, R.N. (2025). Early-life microbiota disruption  
480 by antibiotics elicits fitness trade-offs that differ by sex. *bioRxiv*, 2025.08.26.670495.


- 481 31. Bolyen, E., Rideout, J.R., Dillon, M.R., Bokulich, N.A., Abnet, C.C., Al-Ghalith, G.A.,  
482 Alexander, H., Alm, E.J., Arumugam, M., Asnicar, F., et al. (2019). Reproducible, interactive,  
483 scalable and extensible microbiome data science using QIIME 2. *Nat. Biotechnol.* 37, 852–  
484 857.
- 485 32. Callahan, B.J., McMurdie, P.J., Rosen, M.J., Han, A.W., Johnson, A.J.A., and Holmes, S.P.  
486 (2016). DADA2: High-resolution sample inference from Illumina amplicon data. *Nat.*  
487 *Methods* 13, 581–583.
- 488 33. McDonald, D., Jiang, Y., Balaban, M., Cantrell, K., Zhu, Q., Gonzalez, A., Morton, J.T.,  
489 Nicolaou, G., Parks, D.H., Karst, S.M., et al. (2024). Greengenes2 unifies microbial data in a  
490 single reference tree. *Nat. Biotechnol.* 42, 715–718.

## FIGURES




### Figure 1. Energy balance under intermittent fasting

- (A) Experimental design, n=6 mice/group.
- (B) Cumulative food intake from baseline through day 30 of treatment. Mean ± SEM.
- (C) Daily food intake for each mouse from baseline through day 30 of treatment. Stats are linear mixed effects (LME, fixed effects: feeding status; random effects: mouse ID, day). Daily food intake for AL mice was lower during treatment versus baseline (LME, fixed effects = phase; random effects = mouse ID,  $P_{\text{phase}}=0.005$ ), a result attributable to slowed growth rates as mice aged. Median ± IQR.
- (D) Energy density of feces produced from days 16-30, measured via bomb calorimetry. Stats are Student's t-test. Mean ± SEM.
- (E) Change in body mass relative to day 0. Mean ± SEM.
- (F) Endpoint (day 30) body mass, lean mass, and fat mass, measured via EchoMRI. Stats are Student's t-test. Mean ± SEM.
- (G) Change in body mass as a function of cumulative food intake, excluding fasted days. Stats are LME (fixed effects: cumulative food intake × treatment; random effects: mouse ID, day).




**Figure 2. Short-term impacts of fasting and re-feeding on the gut microbiota**

- (A) Principal coordinate plot of Bray-Curtis distance between fecal microbiota samples during the second and final IF cycles.
- (B) Absolute bacterial density estimated via universal bacterial 16S qPCR. Stats are from LME model (fixed effect: feeding status; random effects: mouse ID, day). Median  $\pm$  IQR.
- (C) Richness of ASVs per sample. Stats are from LME model (fixed effect: feeding status; random effects: mouse ID, day). Median  $\pm$  IQR.
- (D) Bray-Curtis principal coordinate 1 (PCo1) as a function of time, showing IF1:1 versus AL (top) and IF1:2 versus AL (bottom). Mean  $\pm$  SEM.
- (E) Bray-Curtis distance between each mouse and its own baseline days for all baseline, fasted, and fed days. Stats are from LME model (fixed effects: treatment x feeding status; random effects: mouse ID, baseline sample ID). Median  $\pm$  IQR.



### Figure 3. Bacterial genera significantly associated with fasting and/or re-feeding

Rows are genera that were differentially abundant in feces across feeding status, identified using a MaAsLin3 linear mixed effects model (fixed effects: feeding; random effects: mouse ID, source cage ID, day) and remained significant under both the standard unscaled model and when scaling relative abundances by per-sample absolute bacterial abundance. Where genus name is undetermined, the next lowest known taxonomic classification is indicated. Columns represent individual days, ordered by treatment group and feeding status then chronologically. Data are row z-scores of mean relative abundance by genus. Annotations: mean genus relative abundance across all samples (left); feeding status (bottom); phylum categorization of each genus (inner right); significance and direction of feeding effects on genus relative abundance identified by the unscaled MaAsLin3 model (right).



**Figure 4. Examples of differential responses of gut microbial genera to the long- and short-term impacts of intermittent fasting**

- (A) Relative abundance of *Ruminococcus* is elevated only during fasting (fasted:  $\beta=2.51$ ,  $q=1.08 \times 10^{-8}$ ).
- (B) Relative abundance of *Akkermansia* is elevated during fasting and reduced during re-feeding (fasted:  $\beta=1.82$ ,  $q=7.59 \times 10^{-4}$ ; re-fed1:  $\beta=-1.55$ ,  $q=1.94 \times 10^{-5}$ ).
- (C) Relative abundance of *Thomasclavelia* is elevated only during fasting (fasted:  $\beta=3.68$ ,  $q=4.07 \times 10^{-18}$ ).
- (D) Relative abundance of *Lactobacillus* is elevated during re-feeding (re-fed1:  $\beta=1.82$ ,  $q=1.23 \times 10^{-6}$ ; re-fed2:  $\beta=1.66$ ,  $q=1.23 \times 10^{-6}$ ).
- (E) Relative abundance of *Turicibacter* is reduced long-term in IF mice regardless of feeding status (fasted:  $\beta=-2.77$ ,  $q=2.57 \times 10^{-7}$ ; re-fed1:  $\beta=-2.88$ ,  $q=3.49 \times 10^{-7}$ ; re-fed2:  $\beta=-2.14$ ,  $q=0.006$ ).
- (F) Relative abundance of *Hominisplanchenecus* is elevated in IF mice with an exacerbated increase during fasting (fasted:  $\beta=2.60$ ,  $q=2.50 \times 10^{-6}$ ; re-fed1:  $\beta=1.50$ ,  $q=0.020$ ; re-fed2:  $\beta=1.96$ ,  $q=0.001$ ).
- (A-F) Mean  $\pm$  SEM. Statistics are from MaAsLin3 model (fixed effect: feeding status; random effects: mouse ID, source cage ID, day), not scaled to absolute bacterial abundance.  $\beta$ -coefficients indicate log<sub>2</sub> fold change from baseline/AL-fed samples and the q-value is the FDR corrected P-value.